Fanny Villa

Fanny Villa

Auto-generated profile, based on publicly available information

Fanny Villa

Department of Infectious and Tropical Diseases, Hopital Caremeau–CHU de Nimes, Nimes, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2024 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
FVFanny Villa
Fanny Villa
HMHélène Marchandin
Hélène Marchandin
Jean-Philippe LavigneJean-Philippe Lavigne
Jean-Philippe Lavigne
SSSophie Schuldiner
Sophie Schuldiner
NCNicolas Cellier
Nicolas Cellier
PLPaul Loubet
Paul Loubet
SUMMARY: Diabetic foot infections (DFI) are a public health problem worldwide. DFI are polymicrobial, biofilm-associated infections involving complex bacterial communities organized in functional equivalent pathogroups, all including anaerobes. Indeed, multiple pathophysiological factors favor the growth of anaerobes in this context. However, the prevalence, role, and contribution of anaerobes in wound evolution remain poorly characterized due to their challenging detection. Studies based on culture reviewed herein showed a weighted average of 17% of patients with anaerobes. Comparatively, the weighted average of patients with anaerobes identified by 16S rRNA gene sequencing was 83.8%. Culture largely underestimated not only the presence but also the diversity of anaerobes compared with cultivation-independent approaches but both methods showed that anaerobic Gram-negative bacilli and Gram-positive cocci were the most commonly identified in DFI. Anaerobes were more present in deeper lesions, and their detection was associated with fever, malodorous lesions, and ulcer depth and duration. More specifically, initial abundance of Peptoniphilus spp. was associated with ulcer-impaired healing, Fusobacterium spp. detection was significantly correlated with the duration of DFI, and the presence of Bacteroides spp. was significantly associated with amputation. Antimicrobial resistance of anaerobes in DFI remains slightly studied and warrants more consideration in the context of increasing resistance of the most frequently identified anaerobes in DFI. The high rate of patients with DFI-involving anaerobes, the increased knowledge on the species identified, their virulence factors, and their potential role in wound evolution support recommendations combining debridement and antibiotic therapy effective on anaerobes in moderate and severe DFI.

2 January 2026 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
PLPaul Laffont-Lozes
Paul Laffont-Lozes
FVFanny Villa
Fanny Villa
CMCéline Mory
Céline Mory
ASAlbert Sotto
Albert Sotto
PLPaul Loubet
Paul Loubet
RLROMARIC LARCHER
ROMARIC LARCHER
Introduction Infections caused by metallo-β-lactamase-producing Enterobacterales offer limited therapeutic options. Aztreonam–avibactam (ATM-AVI) provides a promising alternative, but its approved intermittent regimen is complex and can lead to substantial drug waste. Methods We describe a case of mastoiditis with a retrotympanic abscess due to OXA-48- and NDM-1-producing Klebsiella pneumoniae, managed with continuous infusion (CI) of ATM-AVI after a full-vial loading dose, supported by therapeutic drug monitoring (TDM) and whole-genome sequencing (EPISEQ CS V2.0, bioMérieux). Results A 35-year-old man previously treated abroad for meningitis and brain abscesses presented with residual deep-seated infection caused by OXA-48- and NDM-1-producing K. pneumoniae. After initial treatment with ceftazidime–avibactam plus aztreonam, therapy was switched to ATM-AVI using a full-vial loading dose followed by CI. TDM demonstrated sustained plasma levels of both drugs, and the patient improved without adverse events. Conclusion CI of ATM-AVI following a high loading dose was feasible, safe, and allowed optimized pharmacokinetic/pharmacodynamic (PK/PD) exposure while preventing drug wastage. Larger studies are warranted to determine the clinical utility of CI ATM-AVI across different MIC ranges.

12 March 2024 in Médecine et Maladies Infectieuses Formation
Verified
Journal Article
Closed access
FVFanny Villa
Fanny Villa
LPLucas Perez
Lucas Perez
VMVincent Le Moing
Vincent Le Moing